Mechanisms underlying Benzyl alcohol cytotoxicity (triamcinolone acetonide preservative) in human retinal pigment epithelial cells

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 7, 2011, Pages 4214-4222

  Chang, Yi Sheng ^a,b   Lin, Chiou Feng ^b   Wu, Chao Liang ^b   Kuo, Pao Ying ^a   Wu, Fong Sen ^b   Shieh, Chi Chang ^a,c   Gean, Po Wu ^b   Chen, Shur Tzu ^b   Chen, Muh Shy ^d   Wu, Wen Chuan ^e   Tai, Ming Hong ^f   Tseng, Sung Huei ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; BENZYL ALCOHOL; CASPASE 3; CASPASE 8; CASPASE 9; REACTIVE OXYGEN METABOLITE; GLUCOCORTICOID; PRESERVATIVE; TRIAMCINOLONE ACETONIDE;

APOPTOSIS; ARTICLE; CELL DEATH; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; NICK END LABELING; PIGMENT EPITHELIUM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL LINE; CELL MEMBRANE POTENTIAL; CELL NUCLEUS; DRUG ADMINISTRATION; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; MITOCHONDRION; NECROSIS; PATHOLOGY; STAINING; TIME; TISSUE DISTRIBUTION;

APOPTOSIS; APOPTOSIS INDUCING FACTOR; BENZYL ALCOHOL; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE; CELL NUCLEUS; DRUG ADMINISTRATION SCHEDULE; ENZYME ACTIVATION; GLUCOCORTICOIDS; HUMANS; MEMBRANE POTENTIALS; MITOCHONDRIA; NECROSIS; PRESERVATIVES, PHARMACEUTICAL; REACTIVE OXYGEN SPECIES; RETINAL PIGMENT EPITHELIUM; SIGNAL TRANSDUCTION; STAINING AND LABELING; TIME FACTORS; TISSUE DISTRIBUTION; TRIAMCINOLONE ACETONIDE;

EID: 80051929939     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6058     Document Type: Article

References (55)

1. Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2001;131:468-471.
2. Bandello F, Polito A, Pognuz DR, Monaco P, Dimastrogiovanni A, Paissios J. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol. 2006;124:643-650.
3. Cardillo JA, Melo LA Jr., Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005;112:1557-1563.
4. Spandau UHM, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas JB. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular edema. Br J Ophthalmol. 2005;89: 999-1003.
5. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112: 1916-1921.
6. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg. 2003;29:27-33.
7. Nicolo M, Ghiglione D, Lai S, Calabria G. Intravitreal triamcinolone in the treatment of serous pigment epithelial detachment and occult choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol. 2005;15:415-419.
8. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113:14-22.
9. Williamson TH, O'Donnell A. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol. 2005;139:860-866.
10. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84:1064-1067.
11. Burk SE, Da Mata AP, Snyder ME, Schneider S, Osher RH, Cionni RJ. Visualizing vitreous using Kenalog suspension. J Cataract Refract Surg. 2003;29:645-651.
12. Yamakiri K, Uchino E, Kimura K, Sakamoto T. Intracameral triamcinolone helps to visualize and remove the vitreous body in anterior chamber in cataract surgery. Am J Ophthalmol. 2004;138: 650-652.
13. Kumagai K. Introduction of a new method for the preparation of triamcinolone acetonide solution as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina. 2003;23:881-882.
14. Kaynak S, Celik L, Kocak N, Oner FH, Kaynak T, Cingil G. Staining of vitreous with triamcinolone acetonide in retained lens surgery with phacofragmentation. J Cataract Refract Surg. 2006;32:56-59.
15. Yamamoto N, Ozaki N, Murakami K. Triamcinolone acetonide facilitates removal of the epiretinal membrane and separation of the residual vitreous cortex in highly myopic eyes with retinal detachment due to a macular hole. Ophthalmologica. 2004;218: 248-256.
16. Fraser EA, Cheema RA, Roberts MA. Triamcinolone acetonideassisted peeling of retinal internal limiting membrane for macular surgery. Retina. 2003;23:883-884.
17. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986;101:190-195.
18. Takeuchi M, Katagiri Y, Usui M. Residual triamcinolone acetonide in the macular hole after vitrectomy. Am J Ophthalmol. 2003;136: 1174-1176.
19. Yamauchi Y, Nakamura H, Hayakawa K, Sawaguchi S. Persistence of triamcinolone acetonide following macular hole surgery. Acta Ophthalmol Scand. 2006;84:711-712.
20. Enaida H, Sakamoto T, Ueno A, et al. Submacular deposition of triamcinolone acetonide after triamcinolone-assisted vitrectomy. Am J Ophthalmol. 2003;135:243-246.
21. Chang YS, Tseng SY, Tseng SH, Wu CL, Chen MF. Triamcinolone acetonide suspension toxicity to corneal endothelial cells. J Cataract Refract Surg. 2006;32:1549-1555.
22. Chang YS, Wu CL, Tseng SH, Kuo PY, Tseng SY. Cytotoxicity of triamcinolone acetonide on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2007;48:2792-2798.
23. Chang YS, Wu CL, Tseng SH, Kuo PY, Tseng SY. In vitro benzyl alcohol cytotoxicity: implications for intravitreal use of triamcinolone acetonide. Exp Eye Res. 2008;86:942-950.
24. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res. 1996;62:155-169.
25. Ho JD, Chen HC, Chen SN, Tsai RJ. Reduction of indocyanine green-associated photosensitizing toxicity in retinal pigment epithelium by sodium elimination. Arch Ophthalmol. 2004;122:871-878.
26. Narayanan R, Mungcal JK, Kenney MC, Seigel GM, Kuppermann BD. Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci. 2006;47: 722-728.
27. Rezai KA, Farrokh-Siar L, Ernest JT, van Seventer GA. Indocyanine green induces apoptosis in human retinal pigment epithelial cells. Am J Ophthalmol. 2004;137:931-933.
28. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1:1458-1461.
29. Lin CF, Chen CL, Chang WT, et al. Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramide and etoposide-induced apoptosis. J Biol Chem. 2004;279:40755-40761.
30. Lin CF, Chen CL, Chang WT, et al. Bcl-2 rescues ceramide-and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation. J Biol Chem. 2005;280:23758-23765.
31. Chen CL, Lin CF, Chiang CW, Jan MS, Lin YS. Lithium inhibits ceramide-and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis. Mol Pharmacol. 2006;70:510-517.
32. Wu YC, Huang YF, Lin CH, Shieh CC. Detection of defective granulocyte function with flow cytometry in newborn infants. J Microbiol Immunol Infect. 2005;38:17-24.
33. Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009;25:113-119.
34. Benda GI, Hiller JL, Reynolds JW. Benzyl alcohol toxicity: impact on neurologic handicaps among surviving very low birth weight infants. Pediatrics. 1986;77:507-512.
35. Brown WJ, Buits NR, Cory Gipson HT, Huston RK, Kennaway NG. Fatal benzyl alcohol poisoning in a neonatal intensive care unit. Lancet. 1982;1:1250.
36. Gershnik J, Boecler B, Ensley H, McCloskey S, George W. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med. 1982;307:1384-1388.
37. Hiller JL, Benda GI, Rahatzad M, et al. Benzyl alcohol toxicity: impact on mortality and intraventricular hemorrhage among very low birth weight infants. Pediatrics. 1986;77:500-506.
38. Deland FH. Intrathecal toxicity studies with benzyl alcohol. Toxicol Appl Pharmacol. 1973;25:153-156.
39. Feasby TE, Hahn AF, Gilbert JJ. Neurotoxicity of bacteriostatic water. N Engl J Med. 1983;308:966-967.
40. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina. 2003;23:686-691.
41. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003;121:1279-1282.
42. Wang LC, Yang CM. Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocul Immunol Inflamm. 2005;13:295-300.
43. Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dose triamcinolone acetonide. Am J Ophthalmol. 2006;141:579-580.
44. Freeman WR, Morrison VL, Cheng L. Author reply. Retina. 2006;26:1100-1101.
45. Morrison VL, Koh HJ, Cheng L, Bessho K, Davidson MC, Freeman WR. Intravitreal toxicity of the Kenalog vehicle (benzyl alcohol) in rabbits. Retina. 2006;26:339-344.
46. Macky TA, Helmy D, El Shazly N. Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study. Graefes Arch Clin Exp Ophthalmol. 2007;245: 817-824.
47. Li Q, Wang J, Yang L, et al. A morphologic study of retinal toxicity induced by triamcinolone acetonide vehicles in rabbit eyes. Retina. 2008;28:504-510.
48. Penha FM, Rodrigues EB, Maia M, et al. Retinal and ocular toxicity in ocular application of drugs and chemicals-Part II: retinal toxicity of current and new drugs. Ophthalmic Res. 2010;44:205-224.
49. Ruiz-Mereno JM, Montero JA, Bayon A, Rueda J, Vidal M. Retinal toxicity of intravitreal triamcinolone acetonide at high doses in the rabbit. Exp Eye Res. 2007;84:342-348.
50. Shaikh S, Ho S, Engelmann LA, Klemann SW. Cell viability effects of triamcinolone acetonide and preservative vehicle formulations. Br J Ophthalmol. 2006;90:233-236.
51. Szurman P, Kaczmarek R, Spitzer MS, et al. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res. 2006;83:584-592.
52. Moulin M, Carpentier S, Levade T, Arrigo AP. Potential roles of membrane fluidity and ceramide in hyperthermia and alcohol stimulation of TRAIL apoptosis. Apoptosis. 2007;12:1703-1720.
53. Barak A, Morse LS, Goldkorn T. Ceramide: a potential mediator of apoptosis in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:247-254.
54. Lenaz G. Role of mitochondria in oxidative stress and ageing. Biochim Biophys Acta. 1998;1366:53-67.
55. Hampton MB, Orrenius S. Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett. 1997;414:552-556.